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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM is to determine whether or not, “Are the use 
of antibiotics an effective treatment for relieving symptoms of depression in adults?” 
 
STUDY DESIGN: Review of three English language primary studies, published between 2010-
2016. 
 
DATA SOURCES: Three randomized controlled trials (RCTs) were found using PubMed- 
NCBI. These studies analyzed the effectiveness of probiotics in adults with symptoms of 
depression.  
 
OUTCOME MEASURED: The main outcome measured was improvement of symptoms of 
depression after the administration of probiotic supplements. Outcomes were assessed using data 
from self-reported questionnaires, which include the Hopkins Symptom Checklist (HSCL-90), 
Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), and the 
Leiden Index of Depression Sensitivity Scale (LEIDS-r). P-values were used to assess the 
significance of outcomes. 
 
RESULTS: All three studies showed improvement in depressive symptoms with probiotic 
supplementation. There were significant decreases in depression scores during post-intervention 
evaluations when compared to pre-assessment data. Differences between probiotic and placebo 
groups were found to be statistically significant in two out of the three studies. Overall, study 
participants who were given probiotics had lower depression scores than those who were given 
the placebo, after probiotic supplementation.  
 
CONCLUSION: The results of the RCTs support probiotics as an effective treatment for 
relieving symptoms of depression in adults. The possibility of probiotic use in depression offers 
a safer and more affordable option in comparison to currently available therapies.  
 
KEY WORDS: Probiotics, Depression. 
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INTRODUCTION 
Major depressive disorder is a complex mental condition that consist of mood, physical 
and cognitive symptoms that can cause significant distress or impairment in social, occupational, 
and in other important areas of function.1 Depression can result from biological factors such as 
familial gene variants and can also be social in nature due to developmental problems and 
adverse life events. Symptoms vary widely but most frequently include anhedonia, withdrawal 
from activities, and feelings of guilt. Also included are inability to concentrate, some cognitive 
dysfunction, anxiety, chronic fatigue, feelings of worthlessness, somatic complaints, loss of 
sexual drive, and thoughts of death.2 To medically diagnose depression, five or more of the 
above symptoms have to be present including either depressed mood and anhedonia for 2 weeks 
and result in impaired social, occupational, or other areas of functioning.1 Depression can be a 
secondary response to a primary medical condition or the psychological effect of medications, 
therefore these are exclusionary criteria for diagnosis.  
Depression is the most common mental disorder in the United States with an estimated 
16.1 million adults having at least one major depressive episode in 2016.3 Depression is also the 
leading cause of disability among people ages 15-44, resulting in almost 400 million disability 
days per year, substantially more than most other physical and metal conditions.4 Depression is 
associated with higher rates of disease and has a major risk of mortality from suicide.5 Patients 
who are depressed with comorbid conditions are at higher risk for hospitalization, tend to have 
longer hospital stays, and have worst outcomes than their non-depressed counterparts.2 The 
economic burden of depression, including workplace costs, direct costs and suicide related costs 
was estimated to be $210.5 billion in 2010.4 Depression is listed among the twenty leading 
principal reasons for outpatient office visits, and it is estimated that 30% of primary care patients 
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have depressive symptoms.2 According to the Center of Disease Control and Prevention (CDC), 
the percentage of physician visits with depression indicated on the medical record was 10.3% in 
2014 and out of all chronic conditions seen in the emergency room, depression made up 8.3% of 
total visits in that same year.6 
There is an established link between mood disorders and gastrointestinal functioning. It is 
known that stress can trigger or exacerbate conditions such as inflammatory bowel and peptic 
ulcer disease. Evidence of this link is shown with the successful use of antidepressant therapies 
in the treatment of inflammatory bowel disease and other gastrointestinal disturbances.7 This 
leads to questioning of the reverse, “Can variations in gastrointestinal functioning impact mood 
disorders?” Recent studies suggest that gut microbiome play a role in the functioning of the 
nervous system through the hypothalamic pituitary-adrenal axis and that bacteria can change 
central nervous system molecules implicated in the pathophysiology of depression.8 If this is 
found to be true, treatment modalities utilizing the effects of probiotics have the potential for 
success in treating depressive symptoms.  
Methods currently used to treat depression include psychotherapy, antidepressants, and 
electroconvulsive therapy (ECT). Milder forms of the disease can be treated with non-
pharmacological means as simple as engaging in relaxation exercises. A combination of 
psychotherapy and antidepressants is recommended in the treatment of depression.2 However, 
psychotherapy is not always affordable and antidepressant medications have many adverse side 
effects. Probiotic therapy is being proposed as a possible treatment option for depression because 
they lack the adverse side effects of antidepressants and are currently readily available to patients 
at a much lower cost than psychotherapy.  
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OBJECTIVE  
 The objective of this selective EBM is to determine whether or not, “Are the use of 
antibiotics an effective treatment for relieving symptoms of depression in adults?” 
METHODS 
Specific search criteria were used in the selection of three studies. The population of the 
studies used for this review included adults of both sexes between the ages of 20-60 years. One 
study worked with patients previously diagnosed with depression, while the remaining studies 
selected subjects with no psychiatric, neurological disorders, nor personal or family history of 
depression. This selection was made to test beneficial effects of probiotics without the 
confounding factors present with ongoing depressive symptomatology.9 In all the studies, 
interventions given to the experimental groups consisted of oral multispecies probiotic 
supplements of different formulations, containing any of the following species: A. casei, L. casei 
L. acidophilus, L. rhamnosus, L. bulgaricus, L. brevis, L.lactis, L. salivarius, L. helveticus, B. 
breve, B. bifidum, B. longum, , B. lactis, S. thermophiles. Control groups were given a visually-
matched placebo. Self-reported questionnaires were given to both groups before and after 
implementation of interventions to assess improvements in symptoms of depression. All studies 
utilized a randomized blind control trial study design to assess outcomes.  
The author, using the key words “depression” and “probiotics” carried out a detailed 
search using PubMed-NCBI. Each of the articles were published in English and featured in peer-
reviewed journals. Each of the articles were selected based on relevance to the clinical question 
and if it included measurable patient-oriented outcomes (POEMS). Inclusion criteria consisted of 
articles that involved randomized controlled trials published between 2010 and 2016. Studies 
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excluded were those that included study subjects aged above or below the desired age range of 
20-60 years. The statistics reported in these three studies included a mean change from baseline, 
p-values, pair samples t-test, non-parametric MWT, Wilcoxon test (WT) and ANOVA. Table 1 
displays the demographics and characteristics of these three studies.  
Table 1: Demographics & Characteristics of included studies  
Study  Type  #Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventio
ns  
Akkasheh10 
(2016) 
RCT  40 20-55 Patients with MDD based 
on DSM-IV criteria with a 
score of ±15 on the 
Hamilton Depression 
Rating Scale 
Age <20 y or >55 y with a 
history of coronary 
infarction, angina pectoris, 
pregnancy or lactation, or 
substance abuse; and taking 
dietary supplements or 
probiotic supplements during 
the previous two months 
5 Probiotic 
Capsule 
QD x 8 
weeks (56 
days)  
Messaoudi7 
(2011) 
RCT  57 30-60 A score of £ 12 on the 
HADS-anxiety subscale 
(HADS-A) and the HADS-
depression subscale 
(HADS-D) and a score of £ 
20 on the HADS total score 
on initial examination. 
 Neurological, psychiatric, 
renal, hepatic, CVD and 
respiratory diseases, food 
allergy, taking psychotropic 
drugs, nutritional 
supplements, melatonin, 
anxiolytics, antidepressants, 
narcotics, hormones, > 5 
cups of coffee or tea/d, 0.2 
liters of cola, 30–40 g of 
chocolate, three glasses of 
wine, or two fermented dairy 
products, smoking more than 
20 cigarettes. 
 
 Pregnant women and 
subjects in another clinical 
study over the past two 
months. 
2 Probiotic 
Powder 
Formulatio
n QD x 30 
days  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Steenberge
n9(2015) 
RCT  40 Mean 
age of 
20 
Non-smokers with no 
cardiac, renal, hepatic 
conditions, allergies, 
intolerance to lactose, 
gluten, prescribed 
medication, drug use, and 
no > 3–5 alcohol 
units/week.  
No psychiatric, 
neurological disorders, no 
personal or family history 
of depression or migraines 
All subjects that did not meet 
the inclusion criteria.  
1 Probiotic 
Food-
Supplemen
t Powder 
QD x 28 
days  
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OUTCOMES MEASURED 
Each outcome measured was a POEM and was measured using self-reported 
questionnaire assessment tools. Questionnaire responses were totaled and scored for each 
participant. Changes in mean total scores before and after probiotic intervention were used to 
help generative conclusions.  Each article used different questionnaire assessment tools. The first 
study by Akkasheh et al. measured the effects of probiotic intake on symptoms of depression 
using the Beck Depression Inventory (BDI). BDI is a self-compiled questionnaire of 21 items in 
multiple-choice format.1 On each item there are four statements and the subjects were instructed 
to choose the one that best described their situation. The participant responses were given the 
scores 0, 1, 2, and 3, with 0 for the normal or least depressive statement and 3 for the most 
depressive statement. Total BDI scores were calculated by adding together the scores of each 
item. Scores range from 0 to 63 (0-13: minimal depression, 14-19: mild depression, 20-28: 
moderate depression and 29-63: severe depression).9 
The second study by Messaoudi et al. used the Hopkins Symptom Checklist-90 (HSCL-
90) and the Hospital Anxiety and Depression Scale (HADS) to address the potential anxiolytic 
effects of probiotic formulations on human distress, anxiety and depression. The HSCL-90 is a 
90-item self-reported multidimensional questionnaire, screening for a broad range of 
psychopathological disorders. It measures nine primary symptom dimensions (somatization, 
obsessive–compulsive, interpersonal sensitivity, depression, anxiety, anger–hostility, phobic 
anxiety, paranoid ideation and psychoticism).7 Each item was rated on a five-point scale, ranging 
from ‘not at all’ to ‘extremely’. The HSCL-90 subscale focused on in this review is depression. 
The HADS is a fourteen-item, four-point scale, self-assessment that ranges from 0 (never) to 4 
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(very often). It is often applied and convenient for measuring psychological distress in subjects 
with somatic or psychosomatic disorders.2 Three sub-scores were obtained: HADS global, 
HADS-A (anxiety subscale) and HADS-D (depression subscale). The HADS-D is the main 
subscale of interest for this review.  
And lastly, the third article by Steenbergen et al. measured the effects of multispecies 
probiotic intervention on cognitive reactivity to sad mood using the revised Leiden Index of 
Depression Sensitivity Scale (LEIDS-r) and the Beck Depression Inventory II (BDI- II). The 
LEIDS-r is a self-report questionnaire with 34 items that assesses to what extent dysfunctional 
thoughts are activated when experiencing mild dysphoria (i.e., it measures cognitive reactivity to 
sad mood, also referred to as vulnerability to depression).9 The scale used in the study consisted 
of 6 subscales that measure vulnerability and a total of 136 points could be obtained from the 
summation of each subscale score. The BDI-II is very similar to BDI, but revised to identify 
symptoms of severe depression and has been found to be a valid indicator of depression.9 
RESULTS 
 The study by Akkasheh et al. included 40 patients diagnosed with MDD, according to 
DSM-IV criteria, of both sexes, ranging in age from 20 to 55 years old. Only 35 people 
completed the trial resulting in 17 subjects in the probiotic experimental group and 18 subjects in 
the placebo-control group. The probiotic group received one probiotic capsule daily for eight 
weeks consisting of three viable and freeze-dried strains of bacteria: Lactobacillus acidophilus (2 
x 109 CFU/g), Lactobacillus casei (2 x 109 CFU/g) and Bifidobacterium bifidum (2 x 109 
CFU/g). Subjects in the placebo group only received starch capsules with no bacterial strains. 
Patients were urged to retain normal routines before treatment to prevent confounding variables. 
Both study groups showed improvement in BDI scores with a decrease in mean values from 
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baseline, as seen in table 2. The placebo group had a mean change of 1.5, which was 
significantly smaller than that of the probiotic group with a mean change of 5.7. Statistical 
analysis based on pair-samples t-test found the group means to be statistically significant with a 
p-value well below 0.05 at 0.001.  
Table 2: Mean change from baseline ± SDs, Akkasheh et al.10 
 BDI total score 
Probiotic Supplementation -5.7 ± 6.4 
Placebo -1.5 ± 4.8 
p= .001 
 
The Messaoudi et al. study population included 57 healthy men and women aged 30-60. 
On initial evaluation, participants had to have a score of less than or equal to 12 on the HADS-A 
and the HADS-D subscale as well as a score of less than or equal to 20 on the HADS global 
subscale to participate in the clinical trial. Two subjects were discarded from the study due to 
unsatisfactory participation. Subjects were divided into the probiotic formulation (PF, n= 26) and 
the placebo (PL, n= 29) group. Once a day for 30 days the PF group consumed a probiotic 
combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175. In 
comparison, the PL group consumed a placebo formulation containing: xylitol, maltodextrin, 
plum flavor and malic acid. When the groups were analyzed using the Mann-Whitney U test 
(MWT), the percentage change in HSCL-90 Depression scores were considered significant with 
a p-value of less than 0.05, as shown in table 3. The median change from baseline was 50% in 
the PF group as opposed to only 25% in the PL group. For the HADS-D scores, the median 
change from baseline was 31.7% in the PF group as opposed to only 16.7% in the PL group. 
Group comparisons for HADS-D scores were not considered to be statistically significant. 
However, the change in baseline median HADS-D score values for the PF group compared to 
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values at follow-up were statistically significant, with a p-value of 0.008 generated by the 
Wilcoxon test. 
Table 3: Median Percentage Change from Baseline in HSCL-90 Depression and HADS-D 
Score Values, Messaoudi et al.7 
 HSCL-90 Depression  HADS-D 
Probiotic formulation (PF) 50%* 31.7% 
Placebo (PL) 25%* 16.7% 
*p< .05 
 
The last study by Steenbergen et al. included a group of 40 healthy adults without any 
current mood disorders with a mean age of 20. Participants were divided evenly into two groups, 
the experimental group received a probiotic food supplement and the control group was given an 
inert placebo. The probiotic food supplement came as a sachet containing a freeze-dried powder 
of a probiotic mixture containing the following bacterial strains: Bifidobacterium bifidum W23, 
Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, L. casei 
W56, Lactobacillus salivarius W24, and Lactococcus lactis (W19 and W58). The visually 
matched placebo contained a freeze-dried powder consisting of maize, starch and maltodextrins. 
Participants were instructed to consume one sachet of their assigned mix per day for a total of 28 
days. Pre and post-intervention questionnaires were administered and analyzed using analysis of 
variance (ANOVA), data shown in table 4. Pre-intervention data was missing for one participant 
in the placebo group. For the probiotic supplementation group, the total mean change in LAID-r 
scores from baseline to endpoint was 9.4: p < .001 and in the placebo group the total mean 
change in scores was 2.4: p = .63. A statistically significant difference was noticed in the 
probiotic group but not in the placebo group. Statistical analysis of group differences was not 
made, so therefore it is unsure if the increased mean change seen in the probiotic group is 
significant in comparison to the placebo group. The total BDI-II scores for the placebo group 
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showed no change from baseline to endpoint and for the probiotic group, a total non-significant 
change in scores of only 0.65 was observed, p-values were not reported. 
Table 4: LEID-r and BDI-II pre and post-intervention scores and standard error of the 
mean (shown in parentheses). Steenbergen et al.9 
 LEID-r Total   BDI-II 
 Pre  Post  Pre  Post  
Probiotics  42.75 (3.24)* 33.35 (3.51)* 7.90 (1.00) 7.25 (1.19) 
Placebo  44.70 (3.24) 42.30 (3.51) 9.10 (1.00) 9.10 (1.19) 
*p< .001 
 
DISCUSSION 
 The probiotic interventions used in the studies discussed in this review were found to 
have a positive effect on symptoms of depression, indicated by the significant overall decrease in 
depression scores during post intervention evaluations. Also, differences between probiotic and 
placebo groups were found to be statistically significant in two out of the three studies. Study 
participants who were given probiotics had lower depression scores than those who were given 
the placebo. This could not be concluded in the Steenbergen et al. study due to lack of analysis.  
It is still a common public misconception that all bacteria are harmful. Many are unaware 
of the beneficial effects of probiotics, commonly referred to as “good bacteria.” The human body 
is heavily dependent on bacterial organisms for digestive and immune health. Preliminary 
research, such as the studies presented in this review, are demonstrating that the effects of 
probiotics can go even further, with data supporting use in mental health illness and neurological 
disorders.7 However, the U.S Food and Drug Administration (FDA) has yet to approve the use of 
probiotics for treatment of any medical conditions.11 Probiotics are currently sold over-the-
counter as a dietary supplement. Products do not need FDA approval to be dispensed or 
marketed.  The two most common bacterial groups found in probiotics are lactobacillus and 
bifibobacterium. These bacteria are similar to those naturally found in our bodies and therefore 
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have low harm risk.11 Use of probiotics are contraindicated in immunocompromised patients, 
those with severe acute pancreatitis or damage to the GI tract.12 Generally, probiotics are well 
tolerated with few adverse side effects. In comparison probiotics are a much safer option than 
antidepressants, which are known to cause unpleasant side effects such as weight gain, sexual 
dysfunction, drowsiness, seizures and GI distress. But worst of all, antidepressants are frequently 
involved in suicidal ingestion and responsible for a large percentage of drug-related deaths.12 
Probiotics can be found in all drugs stores and are relatively inexpensive. The accessibility and 
affordability of probiotics are advantages to care not offered by cognitive behavioral therapy. 
The shortage of mental health professionals and the high cost of psychiatric care proves to be a 
significant barrier to treatment for many with depression.7 Even though insurance companies are 
mandated under the Affordable Care Act to cover mental health services as preventative care, 
many insured have limited coverage or are unable to manage the associated high copays. 
Probiotics have the potential to be useful in the treatment of depression without the adverse side 
effects of antidepressant medications and are more cost-effective than psychotherapy.  
The potential efficacy of probiotics in the treatment of depression is challenged due to 
study limitations. Two key limitations of all three studies were sample size and the lack of 
diversity among the sample population. The sample populations were fairly small and consisted 
primarily of Caucasians and women. The generalizability of study results to the general public is 
limited because effects were seen in such a small number of people and treatment benefits in 
men and diverse groups were largely untested. The study by Akkasheh et al. is the only study 
that assessed the use of probiotics in patients clinically diagnosed with depression, whereas the 
other two studies assessed effects on healthy adults with self-reported symptoms of depression. 
The outcomes seen in healthy adults lacks transferability to clinically depressed patients, who 
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may respond differently to probiotic administration. The accuracy of these studies come into 
question because outcomes were measured primarily based off of self-reported questionnaires. 
There is no reliable way to tell if participants gave accurate responses. Using a more concrete 
measure such as biochemical markers for depression would help to validate results. Lastly, none 
of the studies included dietary measures or controls. They did not track the dietary intake of 
participants during the intervention. Possible consumption of probiotic substances such as 
fermented foods could have indirectly affected the results of the study and ultimately questions 
the reliability of results.  
CONCLUSION 
The three randomized controlled trials discussed in this review showed improvement in 
symptoms of depression after the administration of probiotic supplementation, supporting 
probiotics as an effective treatment for relieving symptoms of depression in adults. Probiotics 
should be considered as an alternative monotherapy or an additional supplemental treatment 
option for people with depression. The possibility of probiotic use in depression offers a safer 
and more affordable option in comparison to currently available therapies.  
Future studies evaluating the effectiveness of probiotics in depression should use larger 
more diverse sample populations to improve generalizability of results. Focused studies on 
patients clinically diagnosed with depression can better predict treatment effect and further 
quantify the benefits of probiotic use. These data along with research comparing probiotics to 
current treatment methods would help to determine whether probiotics should function as 
monotherapy or as adjunctive treatment. Considering the limitations of the studies presented, 
going forward greater care should be taken to control for confounding variables such as diet and 
more reliable measures should be utilized to ensure the accuracy of results.  
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